Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...
Moderna CEO Stéphane Bancel deflected concerns about the new presidential administration's potential impact on life sciences ...
Vaccine maker Moderna had no Valentine’s Day chocolates for investors when its financial results came out Friday. The company ...
The vaccine maker Moderna had no Valentine’s Day chocolates for investors when its fourth-quarter financial results came out ...
Moderna’s norovirus vaccine trial placed on FDA hold over reported case of Guillain-Barré syndrome
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...
Moderna (MRNA) said that the two-season Phase 3 study evaluating the efficacy, safety and immunogenicity of Moderna’s trivalent vaccine against ...
Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...
Moderna is set to release its fourth-quarter earnings on Friday before the opening bell. Here's a look at what to expect in ...
An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...
Moderna reported a Q4 EPS loss of $2.91, missing estimates, with revenue down 66% YoY to $966 million. The company reaffirmed ...
Moderna shares recovered from an early dip premarket despite the biotech's quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, or $2 ...
Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback